<DOC>
	<DOCNO>NCT01653899</DOCNO>
	<brief_summary>This Investigator Initiated , Phase I/II study , Type 1 diabetic participant receive 14 day oral treatment investigational caspase inhibitor drug IDN-6556 follow first islet transplant . Two pilot study propose establish optimal safety efficacy dose IDN-6556 ( 25 mg twice daily ( Pilot 1 ) load dose 100 mg two hour prior transplantation , two 50 mg dos follow transplant ( Day 0 ) ( Pilot 2 ) . This follow 50 mg three time daily ) . Participants pilot study receive islet cell transplant University Alberta 's standard-of-care therapy . Secondary objective include : 1 . To determine proportion subject treat IDN-6556 achieve maintain insulin independence first subsequent islet transplant . 2 . To obtain preliminary data efficacy IDN-6556 maintain adequate immunological protection allo- autoimmunity islet transplant recipient .</brief_summary>
	<brief_title>Caspase Inhibition Islet Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>To eligible participant must T1DM 5 year , complicate least 1 follow situation persist despite intensive insulin management effort : Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 1 episode severe hypoglycemia require third party assistance within 12 month , Clarke score ≥ 4 , HYPO score ≥ 1,000 , lability index ( LI ) ≥ 400 combined Hypo/LI &gt; 400/300 Metabolic instability , characterize erratic blood glucose level interfere daily activity 1 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . 1 . Severe coexist cardiac disease , characterize one condition : ( ) recent myocardial infarction ( within past 6 month ) ; ( b ) leave ventricular ejection fraction &lt; 30 % ; ( c ) evidence ischemia functional cardiac exam . 2 . Active alcohol substance abuse , include cigarette smoking ( must abstinent 6 month prior transplant ) . 3 . Psychiatric disorder make subject suitable candidate transplantation , ( e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication ) . 4 . History nonadherence prescribe regimen . 5 . Active infection include Hepatitis C , Hepatitis B , HIV , TB ( subject positive PPD perform within one year enrollment , history adequate chemoprophylaxis ) . 6 . Any history current malignancy except squamous basal skin cancer . 7 . BMI &gt; 35 kg/m2 screen visit . 8 . Age le 18 great 68 year . 9 . Measured glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 . 10 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . 11 . Clinical suspicion nephritic ( hematuria , active urinary sediment ) rapidly progress renal impairment ( e.g . Increase serum creatinine 25 % within last 36 month ) . 12 . Baseline Hb &lt; 105g/L ( &lt; 10.5 g/dL ) woman , &lt; 120 g/L ( &lt; 12 g/dL ) men . 13 . Baseline screen liver function test outside normal range , exception uncomplicated Gilbert 's Syndrome . An initial LFT panel value &gt; 1.5 time upper limit normal ( ULN ) exclude patient without retest ; test value ULN 1.5 time ULN make , value remain elevated normal limit , patient exclude . 14 . Untreated proliferative retinopathy . 15 . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breast feed . 16 . Previous transplant evidence significant sensitization PRA ( discretion investigator ) . 17 . Insulin requirement &gt; 1.0 U/kg/day 18 . HbA1C &gt; 12 % . 19 . Uncontrolled hyperlipidemia [ fast LDL cholesterol &gt; 3.4 mmol/L ( 133 mg/dL ) , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ( 90 mg/dL ) ] . 20 . Under treatment medical condition require chronic use steroid . 21 . Use coumadin anticoagulant therapy ( except aspirin ) subject PT INR &gt; 1.5 . 22 . Untreated Celiac disease . 23 . Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Type I Diabetes</keyword>
</DOC>